This analysis is by Bloomberg Intelligence Chief Equity Strategist Gina Martin Adams and Equity ... US — including Taiwan Semiconductors, Novo Nordisk and SAP — rose 12.8%, while less-exposed ...

We may receive a commission on purchases made from links. When Bobby and Jamie Deen decided to walk away from "Road Tasted" in 2007, the signs might not have looked very promising for their ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.